^
Association details:
| Biomarker: | MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | bozitinib (APL-101) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Excerpt:
...- Cohort C / MET amplification basket tumor types excluding primary...
Trial ID:
Source:
Title:
Clinical trial to evaluate safety and effectiveness of APL-101 for the treatment of advanced c-Met expressing solid tumors, including NSCLC, and to find the best dose Klinikai vizsgálat az APL-101 biztonságosságának és hatásosságának értékelésére előrehaladott c-Met-et expresszáló szolid tumorok, ideértve az NSCLC-t (nem kissejtes tüdőrák), kezelésére és a legmegfelelőbb adagolás megtalálására
Excerpt:
...Cohort C: Basket Tumor Types (c-Met high-level amplifications)a.Any tumor type regardless of histology, including osimertinib relapsed/refractory NSCLC, excluding NSCLC EXON 14 skip mutation, that meets inclusion criteria c-Met high-level amplificationb.Unresectable or metastatic disease, refractory to standard therapies with no more than three prior lines of therapyc.Not received any c-Met inhibitor 4d. ...
Trial ID:
Less C2 evidence
Source:
Title:
Abstract CT127: A phase I study of cMET inhibitor bozitinib in patients with advanced NSCLC harboring cMET alterations
Published date:
04/27/2020
Excerpt:
Of the 37 enrolled patients, with a median age of 61: 8 had overexpression; 11 had exon 14 skipping; 8 had amplification and 10 patients had more than 1 type of MET alterations. Bozitinib was generally well-tolerated in all cohorts….ORR for patients with overexpression and amplification (N=6) was 50%. ORR for patients harboring both exon 14 skipping and amplification (N=4) was 100%.
DOI:
10.1158/1538-7445.AM2020-CT127
Trial ID:
